

HEMO ORGANIC LIMITED

CIN: - L24231GJ1992PLC018224

Address: - 8-A, Gulnar, Chinar - Gulnar Appt. V V Nagar Road Anand -388001
Email ID: - drdineshpatel@rediffmail.com, Website: - www.hemoorganicltd.com

Date: February 14, 2019

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Dear Sir,

Sub: Submission of Unaudited Financial Result of the Company for the quarter and nine months ended on December 31, 2018 along with Limited Review Report

Ref: Hemo Organic Limited (Security Id/Code: HEMORGANIC / 524590)


In reference to captioned subject and pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the followings:

1. Unaudited Financial Results for the quarter ended on December 31, 2018
2. Limited Review Report

Kindly take the same on your record and disseminate the same on your website and oblige us.

Thanking You,

Yours faithfully,
For, **Hemo Organic Limited**



Dr. Dinesh Patel
Chairman & Managing Director
DIN: - 00481641

Place: Anand

Hemo Organic Ltd

CIN No. L24231GJ1992PLC018224

Registered Office: 8-A, GULNAR, CHINAR - GULNAR APPT. V V NAGAR ROAD ANAND GUJARAT 388001

UNAUDITED FINANCIAL RESULTS (STAND ALONE) FOR THE QUARTER / NINE MONTHS ENDED ON DECEMBER 31, 2018

PART - I

(Rs. in Lakhs)

Sr. No.	Particulars	Quarter ended on			Nine month ended		Year ended
		31.12.2018 (Unaudited)	30.09.2018 (Unaudited)	31.12.2017 (Unaudited)	31.12.2018 (Unaudited)	31.12.2017 (Unaudited)	31.03.2018 (Audited)
I.	INCOME						
	(a) Revenue from operations	2.59	-	-	2.59	8.69	8.69
	(b) Other Income	-	-	-	-	-	0.01
	Total Income	2.59	-	-	2.59	8.69	8.70
II.	EXPENSES						
	(a) Purchases of Stock-in-trade	3.03	-	-	3.04	7.29	7.29
	(b) Changes in stock of finished goods, work-in-progress and stock-in-trade	(0.24)	-	-	2.18	0.58	0.58
	(c) Employee benefit expense	0.66	0.66	0.35	1.98	1.44	1.00
	(d) Finance costs	-	-	-	-	-	-
	(e) Depreciation and amortisation expense	-	-	-	-	-	-
	(f) Impairment expenses/losses	-	-	-	-	-	-
	(g) Other expenses	0.26	0.70	0.59	7.24	7.34	12.61
	Total Expenses (a to g)	3.71	1.36	0.95	14.44	16.65	23.48
III.	Profit before exceptional items and tax (I) - (II)	(1.12)	(1.36)	(0.95)	(11.85)	(7.96)	(14.78)
IV.	Exceptional Items	-	-	-	-	-	-
V.	Profit before tax (III) - (IV)	(1.12)	(1.36)	(0.95)	(11.85)	(7.96)	(14.78)
VI.	Tax Expense						
	(a) Current tax						
	- Current year	-	-	-	-	-	-
	- Prior years	-	-	-	-	-	-
	- MAT Credit (Entitlement)	-	-	-	-	-	-
	(b) Deferred tax	-	-	-	-	-	-
	Total tax expense	-	-	-	-	-	-
VII.	Profit after tax for the period (V) - (VI)	(1.12)	(1.36)	(0.95)	(11.85)	(7.96)	(14.78)
VIII.	Other comprehensive income						
	Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	Remeasurement of the defined benefit liabilities	-	-	-	-	-	-
	Equity instruments through other comprehensive income	-	-	-	-	-	-
	Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	Other comprehensive income, net of tax	-	-	-	-	-	-
IX.	Total comprehensive income for the period	(1.12)	(1.36)	(0.95)	(11.85)	(7.96)	(14.78)
X.	Paid up equity share capital (Face value of Rs. 10 each)	346.59	346.59	346.59	346.59	346.59	346.59
XI.	Reserves i.e. Other Equity	-	-	-	-	-	(321.04)
XII.	Earnings per equity share (Face value of Rs. 10)						
	(1) Basic	(0.03)	(0.04)	(0.03)	(0.34)	(0.23)	(0.43)
	(2) Diluted	(0.03)	(0.04)	(0.03)	(0.34)	(0.23)	(0.43)



Notes :

- 1 The Company operates in a single segment . As per Ind AS 108 on segment reporting issued by the ICAI, the same is considered to constitute as single primary segment. Accordingly, the disclosure requirements of Ind AS 108 are not applicable
- 2 The above standalone financial results were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on February 14, 2019.
- 3 The statutory Auditors of the company have carried out a "Limited Review" of the above result as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The IND AS compliant corresponding figures of the previous year have not been subject to review, however the company's management has exercised necessary due diligence to ensure that such financial results provide true and fair view.
- 4 Earning per share for the quarter and year ended has been calculated as per weighted average formula and diluted Earning per share has been calculated considering proposed issue of equity shares on account of conversion of convertible securities
- 5 Previous period figures have been regrouped and rearranged, whenever considered necessary.
- 6 The Company has adopted Ind AS notified by ministry of corporate affairs w.e.f. 1st April, 2017. Accordingly, the financial results for the quarter / nine month ended 31st december , 2018 are in compliance with Ind AS. Reconciliation of Net profit as per Ind AS and previous IGAAP ("Accounting Standard") is given below

Particulars	Quarter Ended 31.12.2017	Nine Month Ended 31.12.2017
(1) Net Profit (Loss) as per Previous Indian GAAP	(0.95)	(7.96)
(2) Fair Market Valuation of Debentures & Deposits	-	-
(3) Depreciation on fair valuation of Fixed Assets	-	-
(4) Notinal Interest on Deposits received	-	-
(5) Notinal Interest on ZCB	-	-
(6) Deferred Tax impact on above adjustments	-	-
(7) Share Issue Expenses	-	-
(7) Actuarial Gain / Loss on employees benefit	-	-
(8) Total (2 to 6)	-	-
(9) Net Profit (Loss) before OCI as per Ind As (1+8)	(0.95)	(7.96)
(10) Other Comprehensive Income	-	-
(11) Total Comprehensive Income as per Ind AS (9+10)	(0.95)	(7.96)

- 7 There is the possibility that these quarterly / nine month ended yearly financial result may require adjustments before constituting the Final Ind AS financial Statements for the year ending 31st March,2019.

Date: 14th February, 2019
Place: Anand



For, Hemo Organic Ltd.

[Handwritten Signature]

Dr. Dinesh Patel
Chairman & Managing Director
DIN: 00481641

LIMITED REVIEW REPORT OF THE UNAUDITED FINANCIAL RESULTS OF HEMO ORGANIC LIMITED PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 FOR THE QUARTER ENDED 31ST DECEMBER, 2018

To,


The Board of Directors,
HEMO ORGANIC LIMITED

We have reviewed the quarterly unaudited financial results of Hemo Organic Limited for the quarter ended 31ST December, 2018 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement is the responsibility of the Company's management and has been approved by the board of directors. Our responsibility is to issue a report on the statement based on our review.

We conducted our review in accordance with the standards on review engagement (SRE) 2410 "Review of Interim Financial Information Performed by The Independent Auditor of The Entity" issued by the Institute of Chartered Accountants of India. These standards require that we plan and perform the review to obtain Moderate assurance about whether the financial Statement is free of material misstatement. A review is limited primarily to inquire of Company personnel and analytical Procedure applies to financial data and thus provides less assurance than an Audit. We have not performed the Audit and accordingly we do not express an Audit opinion.

We have not audited or reviewed the amounts appearing in the accompanying financial results and other financial information for the three months ended 31ST December, 2018 which have been prepared solely based on the information compiled by the Management.

Except as provided in the para Basis of Disclaimer. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable Indian accounting standards (Ind AS) as per section 133 of the Companies Act, 2013 and other recognised accounting practice and policies has not disclosed the information required to be disclosed in terms of regulations 33 of the SEBI (Listing Obligations



and Disclosure Requirements) Regulations, 2015 SEBI Circular dated July 5, 2016 in this regards including the manner in which it is to be disclosed, or that it contained any material misstatements.

Basis for Disclaimer of Opinion

In the course of carrying out our audit, we have attempted to obtain sufficient and appropriate audit evidence to satisfy ourselves that the items reflected in the financial statements are fairly stated, but failed:

- 1. The Company has not charged depreciation on the fixed assets during the year and accordingly provision of Indian Accounting Standards relating to depreciation and Deferred Tax Asset / Liabilities have not been followed. The management represented that the amount of depreciation being negligible the same has been not been incorporated.***
- 2. We have not been provided with the balance confirmation or any other details for the trade receivable, trade payable, Loans and advances receivable/Payable shown in the books of accounts. In absence of the same we are unable to confirm the balance and nature of the transactions.***
- 3. We have not been able to verify the bank statements of 4 out of 5 accounts, according to the management the other accounts are dormant and therefore the same have not been collected from bank.***

As a result of these matters, we were unable to determine whether any adjustments might have been found necessary in respect of recorded or unrecorded transactions and accounts receivable/payable and Loans and advances receivable/Payable in the Balance Sheet, and the corresponding elements making up the Statement of Profit and Loss.

Date: 14/02/2019
Place : Ahmedabad

For, M A A K & Associates
(Chartered Accountants)
F.R.N.:135024W



AAShah
Archit A. Shah
(Partner)
M. No. : 137390